Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Heron Therapeutics Set to Join Russell 3000 Index
7 hours 50 minutes ago - DJNF
REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 20, 2014--
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, announced today that it is set to join the broad-market Russell 3000 Index, as well as the Russell Global and Russell Micro-Cap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on www.russell.com/indexes.
Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
"We are extremely pleased with Heron's inclusion in the Russell Indexes, " commented Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics. "Heron is working towards several key milestones, including our NDA resubmission for SUSTOL(TM) for the prevention of acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV) planned for the fourth quarter and the initiation of a Phase 1 trial for our post-surgical pain program, expected in the second half. Heron's inclusion in the Russell Indexes will raise the Company's visibility among the investment community at an opportune time, as we move towards these important milestones."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes. Russell calculates more than 700,000 benchmarks daily covering approximately 98 percent of the investable market globally, more than 80 countries and 10,000 securities. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.
About Russell
Russell Investments (Russell) is a global asset manager and one of only a few firms that offers actively managed multi-asset portfolios and services that include advice, investments and implementation. Russell stands with institutional investors, financial advisors and individuals working with their advisors--using the firm's core capabilities that extend across capital market insights, manager research, portfolio construction, portfolio implementation and indexes to help each achieve their desired investment outcomes.
Russell has more than $259 billion in assets under management (as of 3/31/2014) and works with over 2,500 institutional clients, independent distribution partners and individual investors globally. As a consultant to some of the largest pools of capital in the world, Russell has $2.4 trillion in assets under advisement (as of 6/30/2013). It has four decades of experience researching and selecting investment managers and meets annually with more than 2,200 managers around the world. Russell traded more than $1.6 trillion in 2013 through its implementation services business. Russell also calculates approximately 700,000 benchmarks daily covering 98% of the investable market globally, including more than 80 countries and more than 10,000 securities. Approximately $5.2 trillion in assets are benchmarked (as of 12/31/2013) to the Russell Indexes, which have provided investors with 30 years of smarter beta.
Just picked up another nice block at 6.05
Sold today for my 10% gain.
GLTA
I bought more on today's dip.
IMO, 100% gains from these levels by EOY.
I believe we will see a nice run up towards PDUFA date now that we have an affirmative ADCOM panel vote.
This one will require more patience!
Took a bite.
In here with a starter position at 1.08
That's very true if you shorted it from above $3
Yes.
Gap must fill before she jumps over $2!
Congrats to folks buying under $1.80's
ETRM
Seeing big pre-market volume this AM after favorable ADCOM vote.
Should open close to $2.00
The nice volume this AM should allow for a quick gap fill then up to the next resistance level IMO.
I think that a positive ADCOM bodes very well for approval.
The bottom line is the panel felt there was a favorable risk/benefit ratio.
I agree
I don't think they would exercise the shelf down here when they can sell later for much higher PPS.
JMHO
Yes
That's the folks who bought at 1.49-1.56
Once they sell, the price should stair step back up IMO
Gap has to fill in first.
Yes
Tomorrow should see huge gains!
I agree except the lack of volume makes people unload at the lower price when they need to cash out.
Volume fixes this in a hurry, but to increase volume you have to have regular PR's which we don't get.
Until they get a public relations team that can get the word out to investors, we will continue to drift along.
JMHO!
They last reported on April 17th with another positive quarter. They continue to add physician providers so I believe the next Q will be positive again.
I'm expecting the next report in mid-July.
This should continue to climb especially once we get sustained trading volume. IMHO
The last few sessions have seen awesome opportunities to pick up some trading shares IMO.
I added to my core position on yesterday's dip.
GLTA longs!
CRMMF
CRH Medical to present at Bloom Burton & Co. Healthcare Investor Conference
5 days 16 hours 36 minutes ago - DJNF
VANCOUVER, June 11, 2014 /CNW/ - CRH Medical Corporation (TSX: CRH) (OTCQX: CRMMF), a North American medical company focussed on providing physicians with innovative products for the treatment of gastrointestinal diseases, today announced that Edward Wright, CRH's Chief Executive Officer, will present an update on the Company's progress at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18, 2014 at 11:00 a.m. EDT in Toronto.
CRH's corporate presentation will be available on the Company website at http://investors.crhsystem.com following the presentation.
Bloom Burton's third annual healthcare investor conference features Canada's premier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.
About CRH Medical Corporation:
CRH Medical Corporation is North American company focussed on providing physicians with innovative products for the treatment of gastrointestinal diseases. The Company's lead product, the CRH O'Regan System, is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I - IV. The O'Regan System is rapidly emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.
SOURCE CRH Medical Corporation
/CONTACT:
Edward Wright, Chief Executive Officer
CRH Medical Corporation
604.633.1440 x1008
Heron Therapeutics to Present at the 9(th) Annual JMP Securities Healthcare Conference
16 minutes ago - DJNF
REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 12, 2014--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 3:00 p.m. ET in New York City.
A live webcast of this presentation will be available on the Company's website at www.herontx.com in the Investors section. A replay of the presentation will be archived on the site for 90 days.
I just picked up a block of 1,000 at 5.59
Will continue to add over the next few weeks.
I'm in here now with you. Thanks for the tip.
Took a starter position here at .54
Took a bite here today at .54
Small starter position.
I agree that this could work out very nicely in the end.
The 15% dip today could be setting up as a very nice buying opportunity here?
This will be a good one to re-visit in late July
Just bought a block here at 34.80
Looks like a great buying opportunity on today's dip.
Energy co. That are lagging the sector looks like a " no brainier" at this time.
Good luck to you.
Hope it flies to the moon
Just picked up a nice block at $1.48
I'm out at $6.84 (12,000 shares)
Good luck to all longs here
Mild dip here this AM should allow for the next step up here soon.
IMO
I'm with you on that!
Something has to be done about the obesity epidemic in this country, so I think the Feds will be open minded regarding VBLOCK technology!
JMHO
I don't think they are are tapping the shelf.
I believe the shelf is for commercialization after approval.
Just my humble opinion.
Headed to
$6.90 IMO
If I was short ETRM, this is where I would be covering and flipping to a long position.
Hopefully, we will start seeing some covering here soon!
Yes
Once the shorts start to cover, this will jump quickly as it is already "spring loaded".
Looking forward to a big run over the next few days. IMO
Looks like a good buying opportunity today here
I picked up another small block of 1,000 shares today on the dip to 6.18
Yes, but we have time. FDA on June 11.
Should run up this week IMO.
I'm in here as well.
Should be a good one!
Bought more at $36.02